Nanjing Huanbo Biotechnology Co. Ltd. has disclosed proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding agent coupled to a β-adrenergic receptor kinase 1 (BARK1; GRK2) targeting moiety via a linker acting as GRK2 degradation inducers.